Tonix Pharmaceuticals Holding (TNXP) Soars with high volume after Positive Phase 3 RELIEF Study Results
Tonix obtains positive results for its TNX-102 SL 5.6 mg Dose in pain reduction over placebo after a testing time of 14 weeks. Shares of Tonix Pharmaceuticals Holding Corp. (TNXP) are rallying today after the company announced high-end top results for TNX-102 SL in its final phase 3 RELIEF study. The stock is surging with high volume as investors welcome these results as a potential opportunity for the company. TNXP stock has surged from the prior close of $0.63 to $0.91 up by almost 45%, as we write this at 9:48 A.M. EST. The trading volume is up by 108